In our daily series of Q&As, we profile Bioeconomy Science Institute CEO Mark Piper.
CEO says the company has hard worked hard to regain the faith of stakeholders.
The company is targeting $10m in revenue next year.
UPDATE: Nick Grayston says pricing and cost initiatives pay dividends despite lockdowns.
While travel flounders, health insurance soars.
Green Cross Health has teamed up with PEP in the sales process but says it’s early days.
Fire at competitor plant in Japan boosts sales for NZ manufacturer.
Retailer paid back Covid-19 wage subsidy and gave bonus to staff totalling $8.7m.
Kiwi firm Provarko says on-farm biofertiliser-producing, carbon-reducing system is proven overseas.
Soured relations between lender and developer have delayed badly needed homes.
